Effect of berberine on lipid metabolism in patients with type 2 diabetes

Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD

Published in Journal of Clinical Endocrinology and Metabolism

Abstract

Clinical trial demonstrating berberine (500mg twice daily) significantly reduces cholesterol, triglycerides, and LDL while improving insulin sensitivity in type 2 diabetes patients, with mechanisms involving AMPK activation.

Methodology

Randomized controlled trial comparing berberine (500mg three times daily) to metformin (500mg three times daily) in 116 patients with newly diagnosed type 2 diabetes. Assessed fasting blood glucose, HbA1c, lipid profile, insulin sensitivity, and safety. Also measured inflammatory markers and adipokines.

Key Findings

Berberine reduced fasting blood glucose by 25% (from 10.6 to 7.0 mmol/L) HbA1c decreased by 2.0% (from 9.5% to 7.5%) Effects comparable to metformin group Total cholesterol decreased by 18% LDL cholesterol reduced by 21% Triglycerides decreased by 35% HDL cholesterol increased by 2% C-reactive protein (CRP) reduced by 40% Weight loss of 2.3 kg average 34% experienced transient GI side effects (vs 56% with metformin)

Conclusions

Berberine demonstrates anti-diabetic efficacy comparable to metformin with additional benefits on lipid profile and inflammation. The supplement activates AMPK pathway similar to metformin. Berberine represents a promising alternative or adjunct for managing type 2 diabetes and metabolic syndrome, particularly for patients intolerant to metformin.

Limitations

Relatively small sample size Short 12-week duration No long-term safety or efficacy data Did not assess different berberine doses Participants were newly diagnosed - effects in established diabetes unknown No cardiovascular outcome data Mechanism of action not fully elucidated Bioavailability challenges not addressed